Biocartis Group NV (BR:BCART) — Market Cap & Net Worth
Market Cap & Net Worth: Biocartis Group NV (BCART)
Biocartis Group NV (BR:BCART) has a market capitalization of $27.24 Million (€23.30 Million) as of June 17, 2026. Listed on the BR stock exchange, this Belgium-based company holds position #24136 globally and #97 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biocartis Group NV's stock price €0.29 by its total outstanding shares 93915904 (93.92 Million). Review BCART total debt and obligations to assess the company's total debt and financial obligations.
Biocartis Group NV Market Cap History: 2015 to 2026
Biocartis Group NV's market capitalization history from 2015 to 2026. Data shows change from $1.27 Billion to $31.84 Million (-29.49% CAGR).
Index Memberships
Biocartis Group NV is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
BEL All Share
BSPT
|
$854.21 Billion | 0.00% | #99 of 108 |
Weight: Biocartis Group NV's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Biocartis Group NV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biocartis Group NV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.01x
Biocartis Group NV's market cap is 1.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.27 Billion | $13.33 Million | -$39.80 Million | 94.89x | N/A |
| 2016 | $1.05 Billion | $12.10 Million | -$49.78 Million | 86.81x | N/A |
| 2017 | $1.14 Billion | $20.96 Million | -$41.96 Million | 54.57x | N/A |
| 2018 | $952.00 Million | $27.81 Million | -$48.15 Million | 34.23x | N/A |
| 2019 | $547.83 Million | $37.44 Million | -$64.07 Million | 14.63x | N/A |
| 2020 | $445.35 Million | $43.13 Million | -$62.93 Million | 10.33x | N/A |
| 2021 | $346.22 Million | $48.27 Million | -$71.47 Million | 7.17x | N/A |
| 2022 | $57.97 Million | $57.48 Million | -$65.38 Million | 1.01x | N/A |
Competitor Companies of BCART by Market Capitalization
Companies near Biocartis Group NV in the global market cap rankings as of June 17, 2026.
Key companies related to Biocartis Group NV by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #127 globally with a market cap of $177.57 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #182 globally with a market cap of $128.10 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #626 globally with a market cap of $44.18 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #663 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #127 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.57 Billion | $472.63 |
| #182 | Danaher Corporation | NYSE:DHR | $128.10 Billion | $181.35 |
| #626 | IDEXX Laboratories Inc | NASDAQ:IDXX | $44.18 Billion | $573.00 |
| #663 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Biocartis Group NV Historical Marketcap From 2015 to 2026
Between 2015 and today, Biocartis Group NV's market cap moved from $1.27 Billion to $ 31.84 Million, with a yearly change of -29.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €31.84 Million | 0.00% |
| 2025 | €31.84 Million | 0.00% |
| 2024 | €31.84 Million | 0.00% |
| 2023 | €31.84 Million | -45.08% |
| 2022 | €57.97 Million | -83.26% |
| 2021 | €346.22 Million | -22.26% |
| 2020 | €445.35 Million | -18.71% |
| 2019 | €547.83 Million | -42.45% |
| 2018 | €952.00 Million | -16.75% |
| 2017 | €1.14 Billion | +8.89% |
| 2016 | €1.05 Billion | -16.99% |
| 2015 | €1.27 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Biocartis Group NV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $27.24 Million USD |
| MoneyControl | $27.24 Million USD |
| MarketWatch | $27.24 Million USD |
| marketcap.company | $27.24 Million USD |
| Reuters | $27.24 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biocartis Group NV
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progres… Read more